Current status and controversy of neoadjuvant therapy for esophageal squamous cell carcinoma
10.3969/j.issn.1000-8179.2019.09.335
- VernacularTitle:食管鳞癌新辅助治疗现状与争议
- Author:
Yufeng QIAO
1
;
Zhentao YU
Author Information
1. 天津医科大学肿瘤医院食管肿瘤科
- Keywords:
esophageal squamous cell carcinoma;
neoadjuvant therapy;
surgical treatment;
current situation and controversy
- From:
Chinese Journal of Clinical Oncology
2019;46(9):474-479
- CountryChina
- Language:Chinese
-
Abstract:
Surgery is the first choice of treatment for resectable esophageal squamous cell carcinoma. However, for locally advanced patients, the treatment of esophageal cancer requires a more multidisciplinary, comprehensive approach. Nevertheless, there is no unified standard that defines the best comprehensive treatment strategy for esophageal cancer. In recent years, neoadjuvant therapy has been widely considered as the best treatment by practitioners, but there are still many controversies, including those related to the selection of a neoadjuvant therapy scheme, timing of surgery after neoadjuvant therapy, choice of postoperative adjuvant therapy after neoadjuvant therapy, choice of neoadjuvant and adjuvant therapy, and sensitivity testing of neoadjuvant therapy. In this paper, the present situation and controversies regarding the application of neoadjuvant therapy for esophageal squamous cell carcinoma are reviewed systematically.
